Global Market Size, Forecast, and Trend Highlights Over 2025-2037
NTRK Fusion Gene Positive Advanced Solid Tumor Market size was valued at USD 138.94 million in 2024 and is expected to reach USD 282.14 million by 2037, registering around 5.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of NTRK fusion gene positive advanced solid tumor is assessed at USD 145.16 million.
One of the key factors propelling the market is advancements in precision medicine. A novel approach to healthcare, precision medicine is predicated on an individual's distinct genetic composition, way of life, and past medical records. Healthcare professionals may now more accurately diagnose and treat NTRK fusion gene positive advanced solid tumor because of the development of precision medicine. Also, increased spending on treatments with precision medicine will propel the growth of the NTRK fusion gene positive advanced solid tumor market For instance, global investment in precision medicine treatments was estimated to be around 32 billion dollars in 2022. It is anticipated that overall spending will rise to around 124 billion dollars by 2027.
Researchers and medical experts have come a long way in comprehending the genetic alterations that lead to NTRK Fusion Gene Positive Advanced Solid Tumor growth. As a result, novel and cutting-edge therapies that specifically target the genetic abnormalities causing these tumors have been developed. Patients with advanced solid tumors that are positive for the NTRK fusion gene can now benefit from more individualized, focused treatments that are more successful and meet their specific demands.
NTRK Fusion Gene Positive Advanced Solid Tumor Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Trend for Personalized Treatment - By raising the need for genetic testing, the emergence of personalized treatment strategies is also fueling the market expansion for advanced solid tumors that are positive for the NTRK fusion gene. As per a report, by 2022, medicines, diagnostics, and personalized medical care should account for almost 40% of the total. The precise genetic alterations that lead to the formation of NTRK fusion gene-positive advanced solid tumors are found through genetic testing. The NTRK fusion gene positive advanced solid tumor market is expanding due to the growing need for precision medicine specialists such as genetic counsellors and other healthcare experts, who are in high demand due to the emergence of individualized treatment regimens.
- Increased Prevalence of Solid Cancer Types - Since NTRK fusions are present in the majority of solid cancer types, their prevalence rate is higher. This is anticipated to propel the market for advanced solid tumors with NTRK fusion genes. The discovery of novel medications is anticipated to propel the market for NTRK fusion gene-positive advanced solid tumors. NTRK is a distinct gene that has significance in numerous types of cancers. Also, the development of targeted therapies specifically designed to inhibit NTRK fusion proteins has led to improved outcomes for patients with NTRK fusion-positive tumors. For instance, the FDA approved entrectinib (Rozlytrek) on October 20, 2023, for the treatment of solid tumors in children as young as one month old. For those 12 years of age or older, the FDA approved the medication in 2019.
- Growing Technological Advancements in Genetic Testing – Advanced genetic testing methods, such as next-generation sequencing (NGS), are more sensitive and accurate in detecting genetic alterations like NTRK fusions. Also, improved genetic testing allows for earlier detection of NTRK fusion-positive tumors, enabling patients to receive targeted therapies at earlier stages of the disease. For instance, in 2022, the next-generation sequencing (NGS) platform, the CE-IVD designated Ion Torrent Genexus Dx Integrated Sequencer, was introduced by Thermo Fisher Scientific as an automated system that produces data in a single day. With the platform, users may do clinical research and diagnostic testing on a single device-it is intended for use in clinical laboratories. Moreover, genetic testing panels that include a wide range of genetic alterations, including NTRK fusions, are becoming more common in clinical practice.
Challenges
- High Costs Related to the Targeted Therapies – Targeted therapies can be expensive, posing challenges for patient access, especially in regions with limited healthcare resources or inadequate insurance coverage. Therefore, inadequate healthcare infrastructure and exorbitant expenses linked to NTRK fusion gene screening could potentially impede the future expansion of the NTRK fusion gene-positive advanced solid tumor market.
- Complexity in Identifying the Patients may hinder the Market Growth.
- Lack of Skilled Laboratory Technicians May Hamper the Market Growth
NTRK Fusion Gene Positive Advanced Solid Tumor Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.6% |
|
Base Year Market Size (2024) |
USD 138.94 million |
|
Forecast Year Market Size (2037) |
USD 282.14 million |
|
Regional Scope |
|
NTRK Fusion Gene Positive Advanced Solid Tumor Segmentation
Type (Diagnosis, Therapeutic)
Diagnosis segment in the NTRK fusion gene positive advanced solid tumor market is expected to hold a share of 54% during the forecast period. Diagnostic testing is being used more widely as a result of rising healthcare professionals' understanding of the value of NTRK fusion gene testing in determining which patients are eligible for targeted therapy. NTRK fusions can be identified using a variety of techniques, including pan-TRK immunohistochemistry, fluorescence in situ hybridization, and sequencing approaches. In particular, for tumor histologies with a high prevalence of NTRK fusions involving recurrent partners (MASC, infantile fibrosarcomas, secretory breast carcinoma, and cellular or mixed congenital mesoblastic nephromas), FISH and RT-PCR are reasonable alternatives to NGS in the detection of NTRK fusions. These techniques have been successfully used in the clinic. The segment share is increasing in part due to recent approvals.
End-Users (Hospitals, Specialty Clinics, Cancer Centres, Cancer Research Institutes)
Hospitals segment for the NTRK fusion gene positive advanced solid tumor market is expected to hold a share of 43% during the projected period. The healthcare industry, and notably hospitals, is the most lucrative end-user for the NTRK fusion gene-positive advanced solid tumors market. Healthcare facilities are leading the way in the application of NTRK fusion gene-positive advanced solid tumor treatments due to the high incidence of advanced solid tumors and the increasing emphasis on precision medicine. NTRK fusion gene-positive tumors are those that have been identified in a patient with mutant NTRK genes. It is unclear how frequently NTRK fusions occur, even though they are uncommon and represent approximately 1% of solid tumors. The accurate technique for identifying NTRK fusion genes is DNA Next Generation Sequencing (NSG) technology.
Our in-depth analysis of the global NTRK fusion gene positive advanced solid tumor market includes the following segments:
|
Indication |
|
|
Type |
|
|
End-users |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
NTRK Fusion Gene Positive Advanced Solid Tumor Industry - Regional Synopsis
North American Market Forecast
North America NTRK fusion gene positive advanced solid tumor market is poised to hold the largest share of 35% by the end of 2037. The expansion of clinical research and development initiatives is responsible for the growth of the market in the region. Additionally, the increased cases of cancer in the region are also propelling the growth of the market. According to research, 2. 7 million persons in the 27 EU member states are anticipated to receive a cancer diagnosis and approximately 1. 3 million will pass away from the disease in 2020. The region is at the forefront of technical advancement in healthcare, offering access to cutting-edge diagnostic instruments like fluorescence in situ hybridization and next-generation sequencing. Much of the world's oncology clinical trial activity, including studies looking at targeted treatments for cancers that are positive for NTRK fusion, is conducted in this region.
European Market Statistics
NTRK fusion gene positive advanced solid tumor market in Europe is expected to hold a significant share of 28% during the projected period. The adoption of early diagnosis and treatment is driving the growth of the market in the region. Additionally, individuals with NTRK fusion-positive malignancies have access to targeted medicines and diagnostic tests because of the universal healthcare system in many European nations. For instance, Vitrakvi is a cancer medication used to treat solid tumors involving the fusion of the NTRK gene. Rare genetic abnormalities called NTRK gene fusion can be seen in tumors from the lungs, thyroid, and intestines, among other regions of the body. As a result, the European Medicines Agency determined that it could be authorized for use in the EU because its advantages outweigh its hazards. Therefore, these factors are fuelling the NTRK fusion gene positive advanced solid tumor market growth in the region.
Companies Dominating the NTRK Fusion Gene Positive Advanced Solid Tumor Market
- Zai Lab
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pyramid Biosciences Inc.
- Bayer A.G.
- Merck & Co., Inc.
- Hoffman-La Roche AG
- Pfizer Inc.
- Plexxikon
- OncoDNA
- NeoGenomics Laboratories Inc.
- Cephalon, Inc.
Recent Developments
- The National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has granted Breakthrough Therapy Designation for investigational repotrectinib for the treatment of patients with advanced solid tumors with an NTRK gene fusion that has progressed after treatment with TRK tyrosine kinase inhibitors (TKIs). Repotrectinib was designated as a Breakthrough Therapy, based on findings from patients in the Phase 1/2 TRIDENT-1 study who were TKI-pretreated and NTRK-positive, both international and Chinese.
- Pyramid Biosciences, Inc. reports that PBI-200 has been designated as an orphan medication by the FDA for the treatment of patients with NTRK fusion-positive solid tumors, including primary and metastatic brain tumors. PBI-200 is a next-generation inhibitor that is being developed clinically for patients with tropomyosin receptor kinase (TRK) disorders. It is an oral medication that is highly powerful and selective. The inhibitor is made to counteract a variety of on-target resistance mutations that have been observed with first-generation TRK inhibitors in the past.
- Report ID: 5788
- Published Date: Nov 08, 2024
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
NTRK Fusion Gene Positive Advanced Solid Tumor Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
